Rockefeller Capital Management
KRYS icon

Rockefeller Capital Management’s Krystal Biotech KRYS Stock Holding History

Rockefeller Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.7K Sell
217
-14
-6% -$4.18K ﹤0.01% 3103
2026
Q1 		$59.7K Buy
231
+175
+313% +$46.6K ﹤0.01% 3174
2025
Q4 		$13.8K Sell
56
-49
-47% -$10.3K ﹤0.01% 3670
2025
Q3 		$18.5K Buy
+105
New +$15.7K ﹤0.01% 3384
2022
Q3 		– Sell
-42
Closed -$2K – 4154
2022
Q2 		$2K Buy
+42
New +$2.61K ﹤0.01% 3800

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rockefeller Capital Management's KRYS Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Krystal Biotech (KRYS) stake by 6.1% in Q2 2026, selling an estimated $4.18K and leaving 217 shares worth $80.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3103.

Rockefeller Capital Management first reported a position in KRYS in Q2 2022 and has held it in 5 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Rockefeller Capital Management held 217 shares of Krystal Biotech worth $80.7K as of Q2 2026.
  • Rockefeller Capital Management sold 14 Krystal Biotech shares in Q2 2026, an estimated $4.18K.
  • Krystal Biotech made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3103 holding.
  • Rockefeller Capital Management first reported a position in Krystal Biotech in Q2 2022 and has held it in 5 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.